The Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of
lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis
of the DPP/DPPOS. Diabetes Care 2012;35:723–730
In the article listed above, an error was discovered in the calculation of the direct
medical costs of inpatient care outside the DPP/DPPOS. The costs of inpatient care
were underestimated across the lifestyle, metformin, and placebo treatment groups
due to delayed reporting of hospitalizations by some clinical sites and the authors’
failure to count hospitalizations when the study year in which they occurred was initially
unknown. The authors have now corrected this problem. In addition, they have updated
the analyses to include the complete resource utilization and cost data that are newly
available through 10 years of combined DPP/DPPOS follow-up. The authors have also
classified participants who were diagnosed with diabetes at mid-year study visits
as having diabetes during that year.
Tables 1 and 2 show the corrected and updated undiscounted annual direct medical costs
of the interventions and direct medical costs of care outside the DPP/DPPOS per participant.
Table 3 shows the corrected differences in costs and quality-adjusted life-years (QALYs)
and incremental cost-effectiveness ratios adjusted for survival. The revised results
do not change the conclusions of the article. Over 10 years, the total per capita
cost of the lifestyle intervention, that is, the average cost of the lifestyle intervention
plus the average cost of medical care received by a lifestyle participant outside
the DPP/DPPOS, was greater than the total per capita cost of the placebo intervention.
This was true from all three study perspectives (health system, modified societal,
and societal perspectives). Over 10 years, the lifestyle intervention also resulted
in more total QALYs than the placebo intervention. Over 10 years, metformin had a
slightly lower total per capita cost than placebo and yielded approximately the same
number of QALYs as placebo. From a health system perspective, after adjusting for
survival, and with both costs and health outcomes discounted at 3% per year, lifestyle
cost was approximately $13,000 per QALY gained compared with placebo. Metformin was
cost-saving compared with placebo. Compared with metformin, lifestyle cost more but
produced better health outcomes with a cost-effectiveness ratio of approximately $15,000
per QALY gained. DPP group lifestyle was estimated to be slightly more costly but
much more effective than placebo with a cost-effectiveness ratio of $1,000 per QALY
gained.
These updated analyses demonstrate that over 10 years, lifestyle, when compared with
placebo, is cost-effective and metformin is marginally cost-saving. Lifestyle is also
cost-effective when compared with metformin. If a DPP group lifestyle intervention
could be delivered at one-third lower cost than the DPP lifestyle intervention and
achieve the same outcomes, it would be extremely cost-effective compared with placebo.
The corrected Tables 1–3 and Figure 1 appear below. Supplementary Tables 1–4 have
been revised and are available in Supplementary Data online (http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1468/-/DC1).
The entire article including abstract, text, figure, and tables has been corrected
online.
Table 1
Undiscounted, per capita, direct medical costs of the DPP/DPPOS interventions by intervention
group and study year ($)*
Table 2
Undiscounted, per capita, direct medical costs of care outside the DPP/DPPOS by intervention
group and study year, and distribution of undiscounted, per capita, 10-year, direct
medical costs of care outside the DPP/DPPOS by intervention group and type ($)
Table 3
Differences in total costs and QALYs and incremental cost-effectiveness ratios* for
lifestyle and metformin versus placebo and lifestyle versus metformin over 10 years
from three alternative perspectives
Figure 1
A: Cumulative, undiscounted, per participant, direct medical costs of the DPP/DPPOS
interventions by intervention group and study year. B: Cumulative, undiscounted, per
participant, direct medical costs of medical care received outside the DPP/DPPOS by
intervention group and study year. C: Cumulative, undiscounted, per participant, total
direct medical costs of the DPP/DPPOS interventions and medical care received outside
the DPP/DPPOS by intervention group and study year. D: Cumulative, undiscounted, per
participant, total Quality of Well-Being Index by intervention group and year.